Anti-Ret (extracellular)

Antibodies

Antibodies

Israel

Storage before Reconstitution: The antibody ships as a lyophilized powder at room temperature. Upon arrival, it should be stored at -20°C - Storage after Reconstitution: The reconstituted solution can be stored at 4°C for up to 1 week. For longer periods, small aliquots should be stored at -20°C. Avoid multiple freezing and thawing. Centrifuge all antibody preparations before use (10000 x g 5 min).

A Rabbit Polyclonal Antibody to Ret Receptor

Polyclonal

Western blot analysis

25 µl, 50 µl or 0.2 ml double distilled water (DDW), depending on the sample size.

1% BSA, 0.05% NaN3

RET

Human

41116161

The RET proto-oncogene on human chromosome 10q11.2, encodes a receptor tyrosine kinase (RTK) activated by members of the glial cell line-derived neurotrophic factor (GDNF) ligand family (GDNF, neurturin, artemin, and persephin) in conjunction with a ligand-specific coreceptor (GFRα1-4)1. RET belongs to the cadherin superfamily, and it has been suggested that the ret gene is the result of a recombination between a gene encoding a tyrosine kinase receptor and a gene encoding an ancestral cadherin at an early stage of evolution2. The extracellular domain of RET comprises, as observed for other tyrosine kinase receptors, a cysteine-rich domain, but also four cadherin-like domains3.RET signaling is crucial for the development of the enteric nervous system. RET also regulates the development of sympathetic, parasympathetic, motor, and sensory neurons, and is necessary for the postnatal maintenance of dopaminergic neurons. Outside the nervous system, RET is crucial for development of the kidney and plays a key role in spermatogenesis3.RET has attracted considerable clinical interest because of the range of mutations found in diverse conditions that include Hirschsprung disease and a variety of cancers involving the thyroid gland. RET-related cancers with thyroid involvement include sporadic and familial medullary thyroid carcinoma (MTC), multiple endocrine neoplasia 2 (MEN2) syndromes MEN2A and MEN2B, and papillary thyroid carcinoma (PTC)4.